Spark Therapeutics Inc. (NASDAQ:ONCE) was down 6.5% during trading on Wednesday . The company traded as low as $54.07 and last traded at $54.30, with a volume of 338,042 shares changing hands. The stock had previously closed at $58.09.

A number of equities research analysts have recently commented on ONCE shares. Zacks Investment Research cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Royal Bank Of Canada started coverage on shares of Spark Therapeutics in a research report on Tuesday, July 12th. They issued an “outperform” rating and a $70.00 target price for the company. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research report on Thursday, July 14th. SunTrust Banks Inc. increased their target price on shares of Spark Therapeutics from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Tuesday, June 21st. Finally, Chardan Capital set a $35.00 target price on shares of Spark Therapeutics and gave the company a “hold” rating in a research report on Thursday, July 21st. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $61.20.

The company’s market capitalization is $1.66 billion. The firm has a 50-day moving average of $56.63 and a 200 day moving average of $43.58.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.97) by $0.07. During the same quarter in the prior year, the firm earned ($0.60) EPS. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. The business’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts forecast that Spark Therapeutics Inc. will post ($3.94) EPS for the current year.

In other Spark Therapeutics news, Director Anand Mehra sold 500 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $60.00, for a total transaction of $30,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $46.49, for a total transaction of $232,450.00. Following the sale, the chief executive officer now owns 235,000 shares in the company, valued at $10,925,150. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Spark Therapeutics stock. RS Investment Management Co. LLC increased its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,349 shares of the company’s stock after buying an additional 9,957 shares during the period. RS Investment Management Co. LLC owned about 1.83% of Spark Therapeutics worth $20,496,000 as of its most recent filing with the SEC.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.